Q2 2020
Q2 2020 results - Tuesday, July 21, 2020
Media release
Interim financial report (PDF 0.8 MB)
Read the presentation transcript
Download the podcast (MP3 44 MB)
Download the presentation (PDF 2.6 MB)
| Continuing operations1 | |||
| Key figures2 | Q2 2020 (USD m) |
Q2 2019 (USD m) |
% change (USD/cc) |
|---|---|---|---|
| Net sales | 11,347 | 11,764 | -4 (cc: -1) |
| Operating income | 2,352 | 2,663 | -12 (cc: -4) |
| Net income | 1,867 | 2,109 | -11 (cc: -4) |
| EPS (USD) | 0.82 | 0.91 | -10 (cc: -3) |
| Free cash flow | 3,631 | 3,612 | 1 |
Core |
|||
| Operating income | 3,669 | 3,648 | 1 (cc: 6) |
| Net income | 3,108 | 3,096 | 0 (cc: 5) |
| EPS (USD) | 1.36 | 1.34 | 1 (cc: 6) |
- Refers to continuing operations as defined on page 42 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 54 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
XBRL package Q2 2020
Documents Novartis results in XML format in line with requirements of the US Securities and Exchange Commission (SEC).